Thursday September 24, 2020

Amryt seeks to have rare condition drug approved for payment

The Dublin company is in discussion with regulators in Britain and France to have metreleptin, a treatment for abnormal distribution of fat in the body, approved for payment reimbursement

Ian Guider

Markets Editor

9th August, 2020
Joe Wiley, Amryt's chief executive, said last week that it is in discussions with the National Institute for Health and Care Excellence

Amryt, the Dublin-based rare drug developer, is in talks with medicines regulators in Britain and other European countries to get its treatments approved for payment reimbursement.

Britain is one of the remaining large European markets where metreleptin, a treatment for lipodystrophy, is yet to be approved for payment following its launch last year. The medical condition involves an abnormal distribution of fat in the body.

Joe Wiley, Amryt's chief executive, said last week that it...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader



Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.



€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.




90 Day Pass

You can cancel any time.

2 Yearly



Unlimited Access for 2 Years

This product does not auto-renew

Team Pass

Get a Business Account for you and your team

Related Stories

Clinical trials firm reported 10.8% drop in revenues for the three months to the end of June

Ian Guider | 1 month ago

We have the potential to become Europe’s go-to destination for the development of advanced therapy medicinal products

Piotr Kowalski | 3 months ago

The essential ingredients for common drugs are largely produced in the countries worst-hit by Covid-19. We could soon be facing shortages of antibiotics, paracetamol, statins and other medication

Sandra Gannon | 5 months ago